Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.ygyno.2013.07.102
Title: | Outcome of 6 fractions of 5.3 Gray HDR brachytherapy in combination with external beam radiotherapy for treatment of cervical cancer | Authors: | Koh, W.Y. Lim, K. Tey, J. Lee, K.M. Lim, G.H. Choo, B.A. |
Keywords: | Brachytherapy Cervical cancer Long fractionation |
Issue Date: | Oct-2013 | Citation: | Koh, W.Y., Lim, K., Tey, J., Lee, K.M., Lim, G.H., Choo, B.A. (2013-10). Outcome of 6 fractions of 5.3 Gray HDR brachytherapy in combination with external beam radiotherapy for treatment of cervical cancer. Gynecologic Oncology 131 (1) : 93-98. ScholarBank@NUS Repository. https://doi.org/10.1016/j.ygyno.2013.07.102 | Abstract: | Objective. To review the characteristics, outcomes and toxicities of cervical cancer patients treated with 6 fractions of brachytherapy after external beam radiotherapy (EBRT). Methods. All patients diagnosed with cervical cancer from 2000 to 2009 who were referred for radical treatment and who received 6 fractions of brachytherapy were retrospectively reviewed. Overall survival (OS), disease free survival (DFS), local control (LC), distant control (DC) rate, acute and late toxicitieswere the primary endpoints. Results. Thirty-two patients with mainly advanced stage squamous cell carcinoma were identified and reviewed. Patients received EBRT of 45 to 50.4 Gy in 1.8 Gy daily fractions followed by 6 sessions of 3 channel brachytherapy of 5.3 Gy prescribed to point H. Response rates to treatment were good, with no residual disease in 84% six weeks after the completion of treatment.With a median follow up time of 8.1 years, the five-year OS, DFS, LC and distant control rates were 75%, 68.5%, 92.8% and 76.9% respectively. None of the patients developed any G3-4 acute toxicity but one patient who had advanced disease developed G3-4 proctitis with a fistula formation. Conclusions. HDR brachytherapy utilizing 6 fractions of 5.3 Gy prescribed to point H with concurrent chemoradiation is superior in terms of OS and LC to regimens that deliver a lower EQD2 dose to point A/H and is associated with very low rates of toxicities. © 2013 Elsevier Inc. All rights reserved. | Source Title: | Gynecologic Oncology | URI: | http://scholarbank.nus.edu.sg/handle/10635/125426 | ISSN: | 00908258 | DOI: | 10.1016/j.ygyno.2013.07.102 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.